Skip to content

PolyPeptide

Active Public limited companyfounded 2006active for 20 yearsChaussée de Tubize 297, 1420 Braine-l'AlleudKBO/BCE: BE 0879.346.768 subsidiary of #3 company by total assets in Walloon Brabant, Pharmaceuticals sector

Lifetime

20 annual accounts with figures on one time axis
peak of €165.2m in 2023
€156.1m▲ 22.0%
lowest -€36.8m in 2007
€7.2m▲ €10.4m
peak of €103.8m in 2025
€103.8m▲ 7.4%
€226.3m▲ 30.4%
peak of 485 FTE in 2025
485 FTE▲ 3.6%
Board36 names since 2006all names
1 director
Owners4 names in the annual accounts
100% and 1 other
Documentsfilings and deeds
11-06-202650 days before the deadline
2025financial year
Turnover from €127.9m to €156.1mProfit of €7.2m, after a loss and act as permanent representatives 18-11Debts from €173.5m to €226.3mInvestments €23.5mCash from €307,106 to €87,135

Key points

from the 2025 annual accounts

Result

€7.2m €7.2m
-€3.2m2024€7.2m2025

Back in profit in 2025, after a loss of €3.2m in 2024.

Investments

€23.5m 2.1 times depreciation
20212022202320242025

Green is investment, beige is depreciation. Machinery stands 27.0% higher than in 2024.

Staff

499 employees on 31-12-2025
852020211365020226843202443402025

In 2025, 43 employees joined and 40 left. On top of that, 23 agency workers worked there on average.

Payment terms

320 days to suppliers
Suppliers
248 to 320
Customers
89 to 146

PolyPeptide pays its suppliers 72 days later than in 2024. Customers pay 57 days later.

Filings

20 annual accounts since 2006
AprilJune31 JulyOctober2010201520202025

The last five annual accounts were filed 50 to 64 days before the end of the period.

Position in the sector

31.3%

Lower solvency than 80% of companies in pharmaceuticals. Sector median 50.3% · 61 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 527 companies had the same profile as PolyPeptide has now. Each dot stands for 2 companies, two years later.

96.2%
were still trading
3.0%
stopped another way
0.8%
went bankrupt
  • Large
  • 20 years or older
  • solvency 30% or more
  • a profit under 5% of the balance sheet
Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 527 companies, not a prediction for PolyPeptide. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, , since 17-05-2023
Auditor,
  • 100%annual accounts 2025
  • consolidatesannual accounts 2025
Board & ownership

Recent changes

and act as permanent representatives General meeting of 30-09-2025 · Gazette deed
reappointed as statutory auditor acts as permanent representative · General meeting of 21-05-2024 · Gazette deed
New establishment in Beersel Jozef Huysmanslaan 53
1 director appointed, 3 resignations , and resign · appointed as sole director · acts as permanent representative · Board meeting of 23-05-2023 · Gazette deed
All 75 events

Comparable companies

same main activity, similar in size and age
Company
PolyPeptide Braine-l'Alleud €156.1m 10.2% 31.3% 485
Prothya Biosolutions Belgium Brussels €109.1m 6.0% -1.7% 349
BAXALTA BELGIUM MANUFACTURING Lessines €374.2m 8.0% 78.5% 1,196.8
AJINOMOTO OMNICHEM Wetteren €468.2m 8.4% 68.0% 863.4
MECS EUROPE/AFRICA Hoeilaart €44.9m 35.3% 60.5% 23.7
TELIX INNOVATIONS Herstal €243.8m 43.6% 24.6% 19.8
JNTL Consumer Health (Belgium) Antwerp €217.6m 41.9% 85.6% 23.1
-10%0%10%20%€50,000€500,000€5m€50m€500m€5bnPolyPeptideEBIT margin

Grey: the largest companies of the sector (pharmaceuticals (NACE 21)), without their names. Blue: the sector peers from the table.

These companies have the same main activity as PolyPeptide: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100). They are comparable in size and age: total assets between €73m and €713m, founded between 1946 and 2022.

Official details

Source: KBO
Status
Active since 14-02-2006Normal situation
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21100and 5 others
Joint committees
207White-collar workers in the chemical industry
116Chemical industry · annual accounts 2025
Establishment units
2.151.696.2631420 Braine-l'Alleud, since 15-02-2006
2.356.361.8101651 Beersel, since 01-01-2024
Financial year end
31 December
Peppol
Reachable
Company details

Annual accounts 2025

€331.7m▲ 22.4%
Employeeson 31-12-2025
499▲ 0.6%
Filing
Filed on 11-06-2026, 50 days before the end of the filing period
Financials

Insights on PolyPeptide

PolyPeptide has existed since 2006. Turnover grew from €28.0m in 2006 to €156.1m in 2025 and staff from 319.7 to 485 full-time equivalents.

holds all the shares. In June 2023, three directors stepped down.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about PolyPeptide

What is the company number of PolyPeptide?
The company number of PolyPeptide is 0879.346.768. The VAT number is the same number with BE in front: BE 0879.346.768.
Where is PolyPeptide based?
The registered office is at Chaussée de Tubize 297, 1420 Braine-l'Alleud.Company details
What does PolyPeptide do?
According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
What is the legal form of PolyPeptide?
PolyPeptide is a public limited company (NV).
When was PolyPeptide founded?
PolyPeptide was founded on 14-02-2006.
Is PolyPeptide still active?
Yes, PolyPeptide is an active enterprise in the KBO register.
How many employees does PolyPeptide have?
PolyPeptide had an average of 485 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does PolyPeptide fall under?
In its 2025 annual accounts, PolyPeptide states joint committees 207 (White-collar workers in the chemical industry) and 116 (Chemical industry).
What is the turnover of PolyPeptide?
The turnover of PolyPeptide was €156.1m in financial year 2025, according to the filed annual accounts.
Is PolyPeptide profitable?
In financial year 2025, PolyPeptide made a profit of €7.2m.
Where can I find the annual accounts of PolyPeptide?
PolyPeptide filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PolyPeptide due?
PolyPeptide must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.